Table 2

Quality of included trials.

Study

Adequate sequence generation

Allocation concealment

Blinding

Incomplete outcome data addressed

Percentage who completed the trial

Free of selective reporting

Groups comparable at baseline

Sample size calculation


Rosenstock 2009[23]

Unclear

Unclear

Yes, Double blind

Yes

Albi 30 mg QW/Albi 30 mg every two weeks/P: 71.0/75.0/78.4

Yes

Yes

Yes


Apovian 2010[43]

Yes

Yes

Yes, Double blind

Yes

Exe/P: 72.2/72.7

Yes

Yes

Yes


Bergenstal 2009[28]

Yes

Yes

No, Open label

Yes

Exe/BIAsp QD/BIAsp BID: 70.2/83.9/80.6

Yes

Yes

Yes


Bergenstal 2010[37]

Yes

Yes

Yes, Double blind

Yes

Exe/Sita/Pio: 79.4/86.7/79.4

Yes

Yes

Yes


Bunck 2009[29]

Yes

Unclear

Unclear

Yes

Exe/Glar: 83.3/90.9

Yes

Yes

Yes


Davies 2009 (HEELA)[30]

Yes

Unclear

No, Open label

Yes

Exe/Glar: 83.9/88.9

Yes

Yes

Yes


Davis 2007[31]

Unclear

Unclear

No, Open label

Yes

Exe/Ins: 57.6/93.8

Yes

Yes

Yes


DeFronzo 2005[42]

Unclear

Unclear

Yes, Triple blind

Yes

Exe/P: 82.3/78.8

Yes

Yes

Yes


DeFronzo 2010[22]

Yes

Unclear

No, Open label

Yes

Exe/Rosi: 73.3/75.6

Yes

Yes

No


Derosa 2010[27]

Yes

Yes

No, Single blind

Yes

Exe/Glib: 93.7/87.7

Yes

Yes

No


Diamant 2010[34]

Yes

Yes

No, Open label

Yes

Exe/Glar: 89.7/93.7

Yes

Yes

Yes


Drucker 2008[41]

Unclear

Unclear

No, Open label

Yes

Exe/Exe lar: 88.4/86.5

Yes

Yes

Yes


Gao 2009[45]

Yes

Yes

Yes, Double blind

Yes

Exe/P: 81.1/88.9

Yes

Yes

Yes


Gill 2010[26]

Unclear

Unclear

Yes, Double blind

Yes

Exe/P: 78.6/88.5

Yes

Yes

Yes


Heine 2005[32]

Yes

Yes

No, Open label

Yes

Exe/Glar: 80.9/90.6

Yes

Yes

Yes


Kadowaki 2009[20]

Unclear

Unclear

Yes, Double blind

Yes

Exe/P: 83.8/97.5

Yes

Yes

Yes


Kendall 2005[21]

Unclear

Unclear

Yes, Double blind

Yes

Exe/P: 82.6/76.1

Yes

Yes

Yes


Nauck 2007[33]

Yes

Yes

Unclear

Yes

Exe/BIAsp 30 BID: 78.7/89.9

Yes

Yes

Yes


Zinman 2007[67]

Yes

Yes

Yes, Double blind

Yes

Exe/P: 71.1/85.7

Yes

Yes

Yes


Kaku 2010[18]

Unclear

Unclear

Yes, Double blind

Yes

Lir 0.6/Lir 0.9/P: 94.3/95.5/84.1

Yes

Yes

Unclear


Pratley 2010[38]

Yes

Yes

No, Open label

Yes

Lir 1.2/Lir 1.8/Sita: 75.1/86.4/88.6

Yes

Yes

Yes


Marre 2009 (LEAD-1)[39]

Unclear

Unclear

Yes, Double blind

Yes

Lir 1.2/Lir 1.8/Rosi/P:

86.0/91.0/83.6/72.8

Yes

Yes

Yes


Nauck 2009 (LEAD-2)[36]

Yes

Yes

Yes, Double blind

Yes

Lir 1.2/Lir 1.8/Glim/P:

82.1/78.9/86.8/61.2

Yes

Yes

Yes


Zinman 2009 (LEAD-4)[44]

Yes

Yes

Yes, Double blind

Yes

Lir 1.2/Lir 1.8/P: 86.0/74.7/68.4

Yes

Yes

Yes


Russell-Jones 2009 (LEAD-5)[35]

Yes

Yes

Unclear

Yes

Lir 1.8/Glar/P: 90.0/94.4/84.2

Yes

Yes

Yes


Buse 2009 (LEAD-6)[40]

Unclear

Yes

No, Open label

Yes

Lir 1.8/Exe: 86.7/81.0

Yes

Yes

Yes


Nauck 2009[24]

Yes

Yes

Yes, Double blind

Yes

Tas 10 mg QW/Tas 20 mg QW/Tas 20 mg every two weeks/P: 91.8/88.0/93.9/95.9

Yes

Yes

Yes


Ratner 2010[25]

Yes

Unclear

Yes, Double blind

Yes

Tas 20 mg QW/Tas 30 mg QW/Tas 40 mg QW: 90.6/81.8/81.3/96.9

Yes

Yes

No


Albi: Albiglutide; Exe: Exenatide; Exe lar: long acting exenatide; Lir: Liraglutide; Tas: Taspoglutide; BIAsp: Biphasic insulin aspart; Glar: Insulin glargine; Ins: Insulin; Glib: Glibenclamide; Glim: Glimepiride; Pio: Pioglitazone; Rosi: Rosiglitazone; Sita: Sitagliptin; P: Placebo; BID: Twice daily; QD: Once daily; QW: Once weekly; HEELA: Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin; LEAD: Liraglutide Effect and Action in Diabetes

Shyangdan et al. BMC Endocrine Disorders 2010 10:20   doi:10.1186/1472-6823-10-20

Open Data